In Silico and in Vitro Assessment of OATP1B1 Inhibition in Drug Discovery.

The organic anion-transporting polypeptide 1B1 transporter belongs to the solute carrier superfamily and is highly expressed at the basolateral membrane of hepatocytes. Several clinical studies show drug-drug interactions involving OATP1B1, thereby prompting the International Transporter Consortium to label OATP1B1 as a critical transporter that can influence a compound's disposition. To examine OATP1B1 inhibition early in the drug discovery process, we established a medium-throughput concentration-dependent OATP1B1 assay. To create an in silico OATP1B1 inhibition model, deliberate in vitro assay enrichment was performed with publically known OATP1B1 inhibitors, noninhibitors, and compounds from our own internal chemistry. To date, approximately 1200 compounds have been tested in the assay with 60:40 distribution between noninhibitors and inhibitors. Bagging, random forest, and support vector machine fingerprint (SVM-FP) quantitative structure-activity relationship classification models were created, and each method showed positive and negative predictive values >90%, sensitivity >80%, specificity >95%, and Matthews correlation coefficient >0.8 on a prospective test set indicating the ability to distinguish inhibitors from noninhibitors. A SVMF-FP regression model was also created that showed an R2 of 0.39, Spearman's rho equal to 0.76, and was capable of predicting 69% of the prospective test set within the experimental variability of the assay (3-fold). In addition to the in silico quantitative structure-activity relationship (QSAR) models, physicochemical trends were examined to provide structure activity relationship guidance to early discovery teams. A JMP partition tree analysis showed that among the compounds with calculated logP >3.5 and ≥1 negatively charged atom, 94% were identified as OATP1B1 inhibitors. The combination of the physicochemical trends along with an in silico QSAR model provides discovery project teams a valuable tool to identify and address drug-drug interaction liability due to OATP1B1 inhibition.

[1]  K. Maeda.  Organic anion transporting polypeptide (OATP)1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs. , 2015, Biological & pharmaceutical bulletin.

[2]  Richard Svensson,et al.  In Vitro and In Silico Strategies to Identify OATP1B1 Inhibitors and Predict Clinical Drug–Drug Interactions , 2011, Pharmaceutical Research.

[3]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[4]  Michal Vieth,et al.  Structure-guided expansion of kinase fragment libraries driven by support vector machine models. , 2010, Biochimica et biophysica acta.

[5]  Ian A. Watson,et al.  Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux. , 2013, Molecular pharmaceutics.

[6]  Kim E. Garbison,et al.  The Minimum Significant Ratio: A Statistical Parameter to Characterize the Reproducibility of Potency Estimates from Concentration-Response Assays and Estimation by Replicate-Experiment Studies , 2006, Journal of biomolecular screening.

[7]  Yuichi Sugiyama,et al.  Inhibition of Transporter-Mediated Hepatic Uptake as a Mechanism for Drug-Drug Interaction between Cerivastatin and Cyclosporin A , 2003, Journal of Pharmacology and Experimental Therapeutics.

[8]  K. Giacomini,et al.  SLC transporters as therapeutic targets: emerging opportunities , 2015, Nature Reviews Drug Discovery.

[9]  Kwang-Hwi Cho,et al.  Computational classification models for predicting the interaction of compounds with hepatic organic ion importers. , 2015, Drug metabolism and pharmacokinetics.

[10]  P. Neuvonen,et al.  Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake , 2011, Pharmacological Reviews.

[11]  The Development, Characterization, and Application of an OATP1B1 Inhibition Assay in Drug Discovery , 2012, Drug Metabolism and Disposition.

[12]  Kazuya Maeda,et al.  Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. , 2013, Biopharmaceutics & drug disposition.

[13]  M. Niemi,et al.  Cyclosporine A Increases Plasma Concentrations and Effects of Repaglinide , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  Robert P. Sheridan,et al.  Random Forest: A Classification and Regression Tool for Compound Classification and QSAR Modeling , 2003, J. Chem. Inf. Comput. Sci..

[15]  Sanjay K. Nigam,et al.  What do drug transporters really do? , 2014, Nature Reviews Drug Discovery.

[16]  A. Mathiowetz,et al.  Medicinal chemistry design principles for liver targeting through OATP transporters. , 2013, Current topics in medicinal chemistry.

[17]  Lei Zhang,et al.  Comparing Various In Vitro Prediction Criteria to Assess the Potential of a New Molecular Entity to Inhibit Organic Anion Transporting Polypeptide 1B1 , 2016, Journal of clinical pharmacology.

[18]  Matthew L. Danielson,et al.  In Silico ADME Techniques Used in Early-Phase Drug Discovery , 2017 .

[19]  Stefan Brenner,et al.  Identification of Novel Inhibitors of Organic Anion Transporting Polypeptides 1B1 and 1B3 (OATP1B1 and OATP1B3) Using a Consensus Vote of Six Classification Models , 2015, Molecular pharmaceutics.

[20]  P. Selzer,et al.  Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.

[21]  J. Dearden,et al.  QSAR modeling: where have you been? Where are you going to? , 2014, Journal of medicinal chemistry.

[22]  B. Feng,et al.  Physicochemical Property Space of Hepatobiliary Transport and Computational Models for Predicting Rat Biliary Excretion , 2012, Drug Metabolism and Disposition.

[23]  Maykel Pérez González,et al.  Variable selection methods in QSAR: an overview. , 2008, Current topics in medicinal chemistry.

[24]  G. V. van Westen,et al.  Structure-Based Identification of OATP1B1/3 Inhibitors , 2013, Molecular Pharmacology.

[25]  S. Ekins,et al.  Comparative Pharmacophore Modeling of Organic Anion Transporting Polypeptides: A Meta-Analysis of Rat Oatp1a1 and Human OATP1B1 , 2005, Journal of Pharmacology and Experimental Therapeutics.

[26]  T. Ghafourian,et al.  Effect of OATP-binding on the prediction of biliary excretion , 2017, Xenobiotica; the fate of foreign compounds in biological systems.

[27]  J. Venhorst,et al.  Generation of Bayesian prediction models for OATP-mediated drug-drug interactions based on inhibition screen of OATP1B1, OATP1B1∗15 and OATP1B3. , 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[28]  Wei Zhou,et al.  High-Dimensional Descriptor Selection and Computational QSAR Modeling for Antitumor Activity of ARC-111 Analogues Based on Support Vector Regression (SVR) , 2012, International journal of molecular sciences.

[29]  B. Stieger,et al.  Bosentan Is a Substrate of Human OATP1B1 and OATP1B3: Inhibition of Hepatic Uptake as the Common Mechanism of Its Interactions with Cyclosporin A, Rifampicin, and Sildenafil , 2007, Drug Metabolism and Disposition.

[30]  S. Winiwarter,et al.  Modeling Organic Anion-Transporting Polypeptide 1B1 Inhibition to Elucidate Interaction Risks in Early Drug Design. , 2016, Journal of pharmaceutical sciences.

[31]  Ulf Norinder,et al.  Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug–Drug Interactions , 2012, Journal of medicinal chemistry.

[32]  Paul D. Martin,et al.  Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine , 2004, Clinical pharmacology and therapeutics.

[33]  Yuichi Sugiyama,et al.  Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. , 2006, Pharmacology & therapeutics.